.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,466,972

« Back to Dashboard

Claims for Patent: 4,466,972

Title: Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
Abstract:Compounds of formula I, ##STR1## wherein X is oxygen or sulphur, and R.sub.1 -R.sub.6 are various substituents. The compounds are useful for treating coronary insufficiency, intermittent claudication, cerebrovascular insults, spasms in muscles and hypertension.
Inventor(s): Neumann; Peter (Berne, CH)
Assignee: Sandoz Ltd. (Basel, CH)
Application Number:06/359,751
Patent Claims: 1. A compound having the formula ##STR43## wherein R.sub.1 ' is hydrogen or C.sub.1-6 alkyl;

R.sub.2 ' and R.sub.5 ', independently, are hydrogen or C.sub.1-6 alkyl;

R.sub.3 ' and R.sub.4 ', independently, are COOR.sub.7 ' or ##STR44## each R.sub.7 ', independently, is C.sub.1-6 alkyl, C.sub.3-7 -cycloalkyl, C.sub.7-10 phenylalkyl or C.sub.3-6 alkoxyalkyl;

A is C.sub.1-6 alkylene;

each

R.sub.8 ' and R.sub.9 ', independently, is C.sub.1-6 alkyl or C.sub.7-10 phenylalkyl; and

X is oxygen or sulphur,

or a pharmaceutically acceptable acid addition salt of a basic compound of the above formula.

2. A compound of claim 1 wherein R.sub.1 ' is hydrogen.

3. A compound according to claim 1 wherein R.sub.1 ' is hydrogen, R.sub.2 ' and R.sub.5 ' are C.sub.1-6 alkyl, R.sub.3 ' and R.sub.4 ' are COOR.sub.7 ' where R.sub.7 ' is C.sub.1-6 alkyl and X is sulphur.

4. A compound according to claim 3 where R.sub.2 ' and R.sub.5 ' are methyl and R.sub.7 ' is methyl, ethyl or t-butyl.

5. A compound according to claim 4 where R.sub.7 ' is ethyl.

6. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarbo xylic acid diethyl ester.

7. The compound of claim 1 which is 4-(2,1,3-benzothiadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicar boxylic acid dimethyl ester.

8. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-methoxycarbonylpyr idine-5-carboxylic acid isobutyl ester.

9. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-isopropyloxycarbon yl-pyridine-5-carboxylic acid methyl ester.

10. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-isopropyloxyethoxy carbonyl-pyridine-5-carboxylic acid methyl ester.

11. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-ethoxyethoxycarbon yl-pyridine-5-carboxylic acid methyl ester.

12. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-cyclopentyloxycarb onyl-pyridine-5-carboxylic acid methyl ester.

13. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-N-benzyl-N-methyla mino ethoxycarbonyl-pyridine-5-carboxylic acid ethyl ester, or a pharmaceutically acceptable acid addition salt thereof.

14. The compound of claim 1 which is 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3-methoxycarbonyl-py ridine-5-carboxylic acid benzyl ester.

15. The compound of claim 1 which is 4-(2,1,3-benzothiadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-isobutyloxycarb onyl-pyridine-5-carboxylic acid ethyl ester.

16. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-isobutyloxycarbon yl-pyridine-5-carboxylic acid ethyl ester.

17. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-ethoxyethoxycarbo nyl-pyridine-5-carboxylic acid ethyl ester.

18. The compound of claim 1 which is 4-(2,1,3-benzothiadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-ethoxyethoxycar bonyl-pyridine-5-carboxylic acid ethyl ester.

19. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-methoxyethoxycarb onyl-pyridine-5-carboxylic acid methyl ester.

20. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-methoxyethoxycarb onyl-pyridine-5-carboxylic acid isopropyl ester.

21. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-methoxycarbonyl-p yridine-5-carboxylic acid ethyl ester.

22. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-1-propyl-2,6-dimethyl-1,4-dihydro-pyridine-3 ,5-dicarboxylic acid diethyl ester.

23. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-N-benzyl-N-methyl amino ethoxycarbonyl-pyridine-5-carboxylic acid methyl ester, or a pharmaceutically acceptable acid addition salt thereof.

24. A pharmaceutical composition useful in treating coronary insufficiency comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

25. A pharmaceutical composition useful in treating intermittent claudication comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

26. A pharmaceutical composition useful in treating cerebrovascular accidents comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

27. A pharmaceutical composition useful in treating muscular spasms comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

28. A pharmaceutical composition useful in treating hypertension comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

29. The compound of claim 1 which is 4-(2,1,3-benzoxadiazole-4-yl)-2,6-dimethyl-1,4-dihydro-3-phenethyloxycarbo nyl-pyridine-5-carboxylic acid methyl ester.

30. A method of treating coronary insufficiency comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

31. A method of treating intermittent claudication comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

32. A method of treating cerebrovascular accidents comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

33. A method of treating muscular spasms comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.

34. A method of treating hypertension comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc